Skip to main content
SpringerLink
Log in

Fixed-dose naproxen/esomeprazole magnesium: a guide to its use to treat arthritic symptoms and reduce gastric ulcer risk

  • Adis Drug Clinical Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Oral naproxen/esomeprazole magnesium (Vimovo™) is a fixed-dose combination of an NSAID and a proton pump inhibitor. The combination is indicated to provide relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients at risk of developing NSAID-associated gastric ulcers (US), and in patients who are at risk of developing NSAID-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient (EU).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

References

  1. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009 Mar; 104 (3): 728–38

    Article  PubMed  Google Scholar 

  2. Blandizzi C, Tuccori M, Colucci R, et al. Clinical efficacy of esomeprazole in the prevention and healing of gastrointestinal toxicity associated with NSAIDs in elderly patients. Drugs Aging 2008; 25 (3): 197–208

    Article  PubMed  CAS  Google Scholar 

  3. Musumba C, Pritchard DM, Pirmohamed M. Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers. Aliment Pharmacol Ther 2009 Sep 15; 30 (6): 517–31

    Article  PubMed  CAS  Google Scholar 

  4. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996 Jul; 6 (3): 489–504

    PubMed  CAS  Google Scholar 

  5. Chan FK, Abraham NS, Scheiman JM, et al. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008 Nov; 103 (11): 2908–18

    Article  PubMed  CAS  Google Scholar 

  6. Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 2010 Apr; 32 (4): 667–77

    Article  PubMed  CAS  Google Scholar 

  7. van Soest EM, Valkhoff VE, Mazzaglia G, et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut 2011 Dec; 60 (12): 1650–9

    Article  PubMed  Google Scholar 

  8. Goldstein JL, Hochberg MC, Fort JG, et al. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther 2010 Aug; 32 (3): 401–13

    Article  PubMed  CAS  Google Scholar 

  9. Vimovo® (naproxen and esomeprazole magnesium) delayed release tablets: US prescribing information. Wilmington (DE): AstraZeneca LP, 2012 Jan

  10. Vimovo® 500 mg/20 mg modified release tablets: UK prescribing information. Luton: AstraZeneca UK Ltd, 2011 Sep 9

  11. Miner Jr P, Plachetka J, Orlemans E, et al. Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, phase I study in healthy volunteers. Aliment Pharmacol Ther 2010; 32 (3): 414–24

    Article  PubMed  CAS  Google Scholar 

  12. Angiolillo DJ, Hwang C, Datto C, et al. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial. Clin Ther 2011 Dec; 33 (12): 1883–93

    Article  PubMed  CAS  Google Scholar 

  13. Wang-Smith L, Fort J, Zhang Y, et al. Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium. J Clin Pharmacol 2012 May; 52 (5): 670–80

    Article  PubMed  CAS  Google Scholar 

  14. Hochberg MC, Fort JG, Svensson O, et al. Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Curr Med Res Opin 2011; 27 (6): 1243–53

    Article  PubMed  CAS  Google Scholar 

  15. Cryer BL, Sostek MB, Fort JG, et al. A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials. Ann Med 2011; 43 (8): 594–605

    Article  PubMed  CAS  Google Scholar 

  16. Sostek MB, Fort JG, Estborn L, et al. Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers. Curr Med Res Opin 2011; 27 (4): 847–54

    Article  PubMed  CAS  Google Scholar 

  17. Dhillon S. Naproxen/esomeprazole fixed-dose combination for the treatment of arthritic symptoms and to reduce the risk of gastric ulcers. Drugs Aging 2011; 28 (3): 237–48

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements and Disclosures

This article was updated from Drugs & Aging 2011; 28 (3): 237-48,[17] and reviewed by M. Baraka, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt; R. Day, Therapeutics Centre, St Vincent’s Hospital, Sydney, NSW, Australia; E. Obarcanin, Sarajevo, Bosnia and Herzegovina.

The preparation of this article was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the articles. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson & Sohita Dhillon

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sohita Dhillon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyseng-Williamson, K.A., Dhillon, S. Fixed-dose naproxen/esomeprazole magnesium: a guide to its use to treat arthritic symptoms and reduce gastric ulcer risk. Drugs Ther Perspect 28, 1–5 (2012). https://doi.org/10.1007/BF03262111

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03262111

Search

Navigation